UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
X QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 29, 2008
OR
TRANSITION REPORT
PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition
period from________to_______
COMMISSION FILE
NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State of Incorporation)
13-5315170
(I.R.S. Employer Identification No.)
235
East 42nd Street, New York, New York 10017
(Address of principal executive offices) (zip
code)
(212) 573-2323
(Registrant's telephone number)
Indicate by check mark whether the registrant (1) has
filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports) and (2)
has been subject to such filing requirements for the past 90 days.
YES X NO
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer or a smaller
reporting company. See definitions of "large accelerated filer," "accelerated
filer" and "smaller reporting company" in Rule 12b-2 of the
Exchange Act (Check one):
Large accelerated filer X Accelerated
filer Non-accelerated
filer Smaller
reporting company
Indicate by check mark whether the registrant is a shell
company (as defined in Rule 12b-2 of the Exchange Act).
YES NO X
At August 5, 2008, 6,740,994,347 shares of the issuer's
voting common stock were outstanding.
FORM 10-Q
For the Quarter
Ended
June 29, 2008
Table
of Contents
PART I. FINANCIAL
INFORMATION
Page
Item 1.
Financial Statements
Condensed
Consolidated Statements of Income for the three months and six months ended June
29, 2008, and July 1, 2007
Condensed Consolidated
Balance Sheets as of June 29, 2008, and December 31, 2007
Condensed
Consolidated Statements of Cash Flows for the six months ended June 29,
2008, and July 1, 2007
Notes to
Condensed Consolidated Financial Statements
Review Report
of Independent Registered Public Accounting Firm
16
Item 2.
Management's
Discussion and Analysis of Financial Condition and Results of Operations
17
Item 3.
Quantitative
and Qualitative Disclosures About Market Risk
44
Item 4.
Controls and
Procedures
44
PART II. OTHER
INFORMATION
Item 1.
Legal
Proceedings
45
Item 1A.
Risk Factors
47
Item 2.
Unregistered
Sales of Equity Securities and Use of Proceeds
48
Item 3.
Defaults Upon Senior
Securities
48
Item 4.
Submission of
Matters to a Vote of Security Holders
48
Item 5.
Other
Information
48
Item 6.
Exhibits
49
Signature
50
PART
I - FINANCIAL INFORMATION
Item 1. Financial Statements.
PFIZER INC AND
SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
Three
Months Ended
Six
Months Ended
(millions,
except per common share data)
June 29,
2008
July
1, 2007
June 29,
2008
July
1, 2007
Revenues
12,129
11,084
23,977
23,558
Costs and expenses:
Cost of sales(a)
2,289
2,109
4,275
3,996
Selling,
informational and administrative expenses(a)
3,863
3,844
7,355
7,205
Research and
development expenses(a)
1,966
2,165
3,757
3,830
Amortization of
intangible assets
663
783
1,442
1,598
Acquisition-related
in-process research and development charges
156
--
554
283
Restructuring
charges and acquisition-related costs
569
1,051
747
1,863
Other
(income)/deductions - net
(167)
(487)
(500)
(889)
Income from
continuing operations before provision for taxes on income and minority
interests
2,790
1,619
6,347
5,672
Provision for
taxes on income
25
272
788
961
Minority
interests
12
Income from
continuing operations
2,759
1,345
5,547
4,706
Discontinued
operations:
Loss from
discontinued operations - net of tax
(1)
--
(5)
--
Gains/(losses) on
sales of discontinued operations - net of tax
18
(78)
18
(47)
Discontinued
operations - net of tax
17
(78)
13
(47)
Net income
2,776
1,267
5,560
4,659
Earnings per common share - basic:
Income from
continuing operations
0.41
0.19
0.82
0.67
Discontinued
operations - net of tax
--
(0.01)
0.01
(0.01)
Net income
0.41
0.18
0.83
0.66
Earnings per common share -
diluted:
Income from
continuing operations
0.41
0.19
0.82
0.67
Discontinued
operations - net of tax
--
(0.01)
--
(0.01)
Net income
0.41
0.18
0.82
0.66
Weighted-average
shares used to calculate earnings per common share:
Basic
6,732
6,966
6,736
7,009
Diluted
6,748
6,990
6,754
7,033
Cash dividends paid per common
share
0.32
0.29
0.64
0.58
(a)
Exclusive of amortization of
intangible assets, except as disclosed in Note 9B. Goodwill and Other
Intangible Assets: Other Intangible Assets.
See accompanying
Notes to Condensed Consolidated Financial Statements.
PFIZER
INC AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
(millions
of dollars)
June 29,
2008*
Dec. 31,
2007**
ASSETS
Cash and cash equivalents
820
3,406
Short-term investments
25,359
22,069
Accounts receivable, less allowance
for doubtful accounts
10,245
9,843
Short-term loans
1,041
617
Inventories
5,334
5,302
Taxes and other current assets
5,711
5,498
Assets held for sale
141
114
Total current assets
48,651
46,849
Long-term
investments and loans
7,105
4,856
Property, plant and equipment, less
accumulated depreciation
14,925
15,734
Goodwill
21,704
21,382
Identifiable
intangible assets, less accumulated amortization
19,875
20,498
Other assets,
deferred taxes and deferred charges
4,255
5,949
Total assets
116,515
115,268
LIABILITIES
AND SHAREHOLDERS' EQUITY
Short-term borrowings, including
current portion of long-term debt
9,448
5,825
Accounts payable
1,928
2,270
Dividends payable
2,147
2,163
Income taxes payable
930
1,380
Accrued compensation and related
items
1,640
1,974
Other current liabilities
7,100
8,223
Total current liabilities
23,193
21,835
Long-term debt
7,246
7,314
Pension benefit
obligations
2,487
2,599
Postretirement
benefit obligations
1,746
1,708
Deferred taxes
5,885
7,696
Other taxes
payable
6,605
6,246
Other
noncurrent liabilities
2,635
2,746
Total liabilities
49,797
50,144
Minority interests
149
114
Preferred stock
81
93
Common stock
443
442
Additional
paid-in capital
69,996
69,913
Employee
benefit trust, at fair value
(399)
(550)
Treasury stock
(57,385)
(56,847)
Retained
earnings
50,912
49,660
Accumulated
other comprehensive income
2,921
2,299
Total shareholders' equity
66,569
65,010
Total liabilities and shareholders'
equity
116,515
115,268
* Unaudited.
** Condensed from audited
financial statements.
See accompanying
Notes to Condensed Consolidated Financial Statements.
PFIZER INC AND
SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Six Months
Ended
(millions
of dollars)
June 29,
2008
July 1,
2007
Operating
Activities:
Net income
5,560
4,659
Adjustments to
reconcile net income to net cash provided by operating activities:
Depreciation
and amortization
2,716
2,712
Share-based
compensation expense
166
228
Acquisition-related
in-process research and development charges
554
283
Deferred taxes
from continuing operations
439
(951)
Other non-cash
adjustments
509
(4)
Changes in
assets and liabilities (net of businesses acquired and divested)
(1,631)
(2,019)
Net cash provided by operating
activities
8,313
4,908
Investing Activities:
Purchases of
property, plant and equipment
(868)
(757)
Purchases of
short-term investments
(16,106)
(10,738)
Proceeds from sales
and redemptions of short-term investments
12,463
17,101
Purchases of
long-term investments
(3,856)
(1,243)
Proceeds from sales
and redemptions of long-term investments
632
22
Purchases of
other assets
(32)
(82)
Acquisitions,
net of cash acquired
(962)
(463)
Other investing
activities
(219)
(293)
Net cash (used in)/provided by
investing activities
(8,948)
3,547
Financing Activities:
Increase in
short-term borrowings, net
16,310
78
Principal
payments on short-term borrowings
(14,097)
(763)
Proceeds from
issuances of long-term debt
602
1,243
Principal
payments on long-term debt
--
(60)
Purchases of
common stock
(500)
(4,999)
Cash dividends
paid
(4,277)
(4,040)
Stock option
transactions and other
33
383
Net cash used
in financing activities
(1,929)
(8,158)
Effect of
exchange-rate changes on cash and cash equivalents
(22)
14
Net (decrease)/increase
in cash and cash equivalents
(2,586)
311
Cash and cash
equivalents at beginning of period
3,406
1,827
Cash and cash
equivalents at end of period
820
2,138
Supplemental
Cash Flow Information:
Cash paid
during the period for:
Income taxes
1,056
3,672
Interest
446
354
See accompanying
Notes to Condensed Consolidated Financial Statements.
PFIZER
INC AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1. Basis of
Presentation
We prepared the condensed
consolidated financial statements following the requirements of the Securities
and Exchange Commission (SEC) for interim reporting. As permitted under those
rules, certain footnotes or other financial information that are normally
required by accounting principles generally accepted in the United States of
America (U.S. GAAP) can be condensed or omitted. Balance sheet amounts and
operating results for subsidiaries operating outside the U.S. are as of and for
the three-month and six-month periods ended May 25, 2008, and May 27, 2007.
Revenues, expenses, assets and
liabilities can vary during each quarter of the year. Therefore, the results
and trends in these interim financial statements may not be representative of
those for the full year.
We are responsible for the unaudited
financial statements included in this document. The financial statements
include all normal and recurring adjustments that are considered necessary for
the fair presentation of our financial position and operating results.
The information included in this
Quarterly Report on Form 10-Q should be read in conjunction with the
consolidated financial statements and accompanying notes included in Pfizer's
Annual Report on Form 10-K for the year ended December 31, 2007.
Note 2. Adoption of New
Accounting Policies
As of January 1, 2008, we adopted on
a prospective basis certain required provisions of Statement of Financial
Accounting Standards (SFAS) No. 157, Fair Value Measurements, as amended
by Financial Accounting Standards Board (FASB) Financial Staff Position (FSP) No. 157-2,
Effective Date of FASB Statement No. 157. Those provisions relate to our
financial assets and liabilities carried at fair value and our fair value
disclosures related to financial assets and liabilities. SFAS 157 defines fair
value, expands related disclosure requirements and specifies a hierarchy of
valuation techniques based on the nature of the inputs used to develop the fair
value measures. Fair value is defined as the price that would be received to
sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. There are three levels of inputs
to fair value measurements - Level 1, meaning the use of quoted prices for
identical instruments in active markets; Level 2, meaning the use of quoted
prices for similar instruments in active markets or quoted prices for identical
or similar instruments in markets that are not active or are directly or
indirectly observable; and Level 3, meaning the use of unobservable inputs.
Observable market data should be used when available.
Many, but not all, of our financial
instruments are carried at fair value. For example,
substantially all of our cash equivalents, short-term investments and long-term
investments are classified as available-for-sale securities and are carried at
fair value, with unrealized gains and losses, net of tax, reported in Other
comprehensive income. Derivative financial instruments are carried
at fair value, with changes in fair value reported in various balance sheet
categories (see both Note 10 D. Financial Instruments: Derivative Financial
Instruments and Hedging Activities in our Annual Report on Form 10-K for the
year ended December 31, 2007, and Note 7C. Financial Instruments: Derivative
Financial Instruments and Hedging Activities in this Quarterly Report) and
ultimately, in Other (income)/deductions - net. Virtually all of our
valuation measurements are Level 2 measurements. The adoption of SFAS 157 did
not have a significant impact on our consolidated financial statements. We did
not elect to adopt SFAS 157 for acquired nonfinancial assets and assumed nonfinancial
liabilities.
Emerging Issues Task Force (EITF)
Issue No. 07-3, Accounting for Nonrefundable Advance Payments for Goods or
Services to Be Used in Future Research and Development Activities, became
effective for new contracts entered into on or after January 1, 2008. EITF
Issue No. 07-3 requires that non-refundable advance payments for goods and
services that will be used in future research and development (R&D)
activities be expensed when the R&D activity has been performed or
when the R&D goods have been received rather than when the payment is made.
The adoption of EITF Issue No. 07-3 did not have a significant impact on our consolidated
financial statements.
Note 3. Acquisitions
During the first six months of 2008
and 2007, we acquired the following:
In the second quarter of 2008, we
acquired Encysive Pharmaceuticals Inc. (Encysive), a biopharmaceutical
company, whose main product (Thelin), for the treatment of pulmonary arterial
hypertension, is commercially available in much of the E.U., is approved in
certain other markets, and is under review by the Food and Drug
Administration (FDA). The cost of acquiring Encysive, through a tender offer
and subsequent merger, was approximately $200 million, including
transaction costs. Upon our acquisition of Encysive, Encysive's change of
control repurchase obligations under its $130 million 2.5% convertible
notes came into effect and, as such, Encysive repurchased the convertible
notes in consideration for their par value plus accrued interest in June 2008.
In addition, in the second quarter of 2008, we acquired Serenex, Inc.
(Serenex), a privately held biotechnology company with SNX-5422, an oral Heat
Shock Protein 90 (Hsp90) inhibitor currently in Phase I trials for the
potential treatment of solid tumors and hematological malignancies and an
extensive Hsp90 inhibitor compound library, which has potential uses in
treating cancer, inflammatory and neurodegenerative diseases. In connection
with these acquisitions, we recorded $156 million in Acquisition-related
in-process research and development charges and approximately $450
million in intangible assets.
In the first quarter of 2008, we
acquired CovX, a privately held biotherapeutics company specializing in
preclinical oncology and metabolic research and the developer of a
biotherapeutics technology platform that we expect will enhance our biologic
portfolio. Also in the first quarter of 2008, we acquired all the outstanding
shares of Coley Pharmaceutical Group, Inc., (Coley), a biopharmaceutical
company specializing in vaccines and drug candidates designed to fight
cancers, allergy and asthma disorders, and autoimmune diseases, for
approximately $230 million. In connection with these and two smaller
acquisitions related to Animal Health, we recorded $398 million in Acquisition-related
in-process research and development charges.
In the first quarter of 2007, we
acquired BioRexis Pharmaceutical Corp., a privately held biopharmaceutical
company with a number of diabetes candidates and a novel technology platform
for developing new protein drug candidates, and Embrex, Inc., an animal
health company that possesses a unique vaccine delivery system known as
Inovoject that improves consistency and reliability by inoculating chicks
while they are still inside the egg. In connection with these and other small
acquisitions, we recorded $283 million in Acquisition-related
in-process research and development charges.
Note 4. Cost-Reduction
Initiatives
The costs incurred in connection with
our cost-reduction initiatives follow:
Three
Months Ended
Six
Months Ended
(millions
of dollars)
June
29,
2008
July 1,
2007
June
29,
2008
July 1,
2007
Implementation
costs(a)
405
317
762
491
Restructuring
charges(b)
562
1,035
739
1,830
Total costs
related to our cost-reduction initiatives
967
1,352
1,501
2,321
(a)
For
the second quarter of 2008, included in Cost of sales ($210 million),
Selling, informational and administrative expenses ($100 million), Research
and development expenses ($94 million), and Other (income)/deductions
- net ($1 million). For the second quarter of 2007, included
in Cost of sales ($170 million), Selling, informational and
administrative expenses ($79 million), Research and development
expenses ($131 million) and Other (income)/deductions -
net
($63 million income). For the first six months of 2008, included in Cost
of sales ($348 million), Selling, informational and
administrative expenses ($175 million), Research and development
expenses ($240 million), and Other (income)/deductions - net
($1 million income). For the first six months of 2007, included in Cost
of sales ($264 million), Selling, informational and
administrative expenses ($128 million), Research and development
expenses ($162 million) and Other (income)/deduction -
net
($63 million income).
(b)
Included
in Restructuring charges and acquisition-related costs.
Through June 29, 2008, the
restructuring charges primarily relate to our plant network optimization
efforts and the restructuring of our U.S. marketing and worldwide research and
development operations, while the implementation costs primarily relate to accelerated
depreciation of certain assets, as well as system and process standardization
and the expansion of shared services.
The components of restructuring charges
associated with our cost-reduction initiatives follow:
(millions
of dollars)
Costs
Incurred
Through
June 29,
2008
Activity
Through
June 29,
2008
(a)
Accrual
as of
June 29,
2008
(b)
Employee
termination costs
3,391
2,395
996
Asset
impairments
1,215
1,215
--
Other
390
294
96
Total